Review
Oncology
Juan A. Marin-Jimenez, Sandra Garcia-Mulero, Xavier Matias-Guiu, Josep M. Piulats
Summary: Immunotherapy has revolutionized the treatment of endometrial cancer by targeting different molecular subtypes and tumor microenvironment features.
CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Bruno Bockorny, Joseph E. Grossman, Manuel Hidalgo
Summary: Pancreatic ductal adenocarcinoma (PDAC) remains a challenging cancer to treat. Chemotherapy has limited benefits and immunotherapy has made little progress. However, recent advances in understanding the tumor microenvironment and new approaches to immunotherapy have provided hope. Improvements in preclinical models, targeting the tumor microenvironment, and identifying biomarkers will likely lead to better selection of patients who could benefit from immunotherapy. Urgent research is needed to design effective combination trials to cure patients with PDAC.
CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Tine J. Monberg, Troels H. Borch, Inge M. Svane, Marco Donia
Summary: Treatment with tumor-infiltrating lymphocytes (TIL) has been proven to be safe, feasible, and effective for patients with metastatic melanoma. However, its implementation on a larger scale is currently limited due to the lack of regulatory approvals. This review discusses the current knowledge of TIL therapy and addresses the practical, logistic, and economic challenges associated with its widespread implementation.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Louise Ferrall, Ken Y. Lin, Richard B. S. Roden, Chien-Fu Hung, T. -C. Wu
Summary: Cervical cancer, primarily caused by persistent high-risk HPV infection, remains the fourth most common cancer affecting women worldwide. Current treatments, such as radiotherapy, chemotherapy, and surgical resection, have limited efficacy and significant side effects against advanced disease. Immunotherapy shows promise in reversing immunosuppressive environments and enhancing T-cell functioning to improve treatment success.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Diwakar Davar, Hassane M. Zarour
Summary: The gut microbiome plays a significant role in immune checkpoint inhibitor therapy, and optimizing microbiota composition may improve immunotherapy outcomes.
CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Aliyah Pabani, Justin F. Gainor
Summary: The clinical development of cytokines as cancer therapeutics is limited due to toxicities and modest efficacy. Immunocytokines, a new generation of cytokines, use antibodies as vehicles to deliver immunomodulatory agents to improve therapeutic index.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Natalia Aptsiauri, Federico Garrido
Summary: HLA class I molecules play a crucial role in tumor recognition and T cell-mediated elimination, and loss of tumor HLA class I expression reduces antigen presentation and facilitates cancer immune evasion. This review summarizes the current advances in understanding the mechanisms of MHC/HLA class I alterations during tumor progression and highlights the importance of detecting and correcting tumor HLA expression absence to improve immunotherapy protocols.
CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Sophia Z. Shalhout, Howard L. Kaufman, Kevin S. Emerick, David M. Miller
Summary: Nonmelanoma skin cancer is the most common malignancy in humans, with keratinocyte carcinomas being the most frequent subtype. The incidence of this cancer is rising due to aging population and increased ultraviolet radiation exposure. Immunotherapy has emerged as a new treatment option for advanced cases not amenable to surgery and/or radiation.
CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Sylvain Ladoire, Cedric Rebe, Francois Ghiringhelli
Summary: Immune-checkpoint inhibitors have significantly impacted cancer management, but resistance remains a major issue. To overcome this, combination strategies with other therapies are being explored.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Walther Brochier, Orian Bricard, Pierre G. Coulie
Summary: T cells play a crucial role in the immune response against tumors by recognizing tumor-specific antigens presented by HLA molecules on tumor cells. Immune checkpoint therapy (ICT) can reactivate existing tumor-specific T cells, even without identifying the specific antigens. To minimize the activation of non-tumor-specific T cells, immunizations targeting tumor-specific antigens are considered. However, identifying these antigens is challenging for certain tumors. In this review, we discuss the current understanding of human tumor-specific and tumor-associated antigens and their potential use in cancer immunotherapy.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
John Anderson, Robbie G. Majzner, Paul M. Sondel
Summary: Immunotherapy for neuroblastoma presents a challenge, but targeting GD2 with antibodies has dramatically improved survival rates for children with high-risk neuroblastoma. Continued efforts to identify new immune targets and treatment methods are being explored to more effectively treat neuroblastoma.
CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Paola Allavena, Clement Anfray, Aldo Ummarino, Fernando Torres Andon
Summary: Tumor-associated macrophages (TAMs), influenced by cancer cell-derived factors, play a crucial role in immunosuppression, tumor growth, and distant metastasis. Accurate quantification and characterization of TAMs in the tumor microenvironment have gained prognostic value, with increasing interest in therapeutic manipulation strategies to enhance antitumor responses. Early-phase clinical trials and experimental models show promising results in targeting and reprogramming TAMs, suggesting a potential for synergizing with current therapies.
CLINICAL CANCER RESEARCH
(2021)
Review
Oncology
Adam S. Sperling, Kenneth C. Anderson
Summary: One hallmark of cancer is the ability of tumor cells to evade and suppress the immune system, with multiple myeloma being a prime example. Decades of research have led to the discovery of various therapeutic agents, including those that alter immune interactions to combat myeloma. Progress in immunotherapy offers hope for a potential cure for this deadly disease.
CLINICAL CANCER RESEARCH
(2021)
Review
Oncology
Justin D. Clubb, Torahito A. Gao, Yvonne Y. Chen
Summary: The development of modern synthetic-biology tools has revolutionized cellular treatments, particularly in anticancer immunotherapy. The FDA has approved six chimeric antigen receptor-modified T-cell products in the last 5 years, demonstrating the potential of engineered T cells in treating hematologic malignancies. Natural killer (NK) cells, with their potent cytotoxic activities and allogeneic capabilities, have emerged as an attractive alternative to T-cell therapies. However, both T cells and NK cells face challenges such as antigen escape, tumor microenvironment immunosuppression, and potential toxicity. Synthetic-biology strategies have been developed to address these obstacles, primarily in the T-cell context. This review explores the strategies, applications, and clinical translation opportunities and challenges for NK-cell therapies.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Iris Nederlof, Leonie Voorwerk, Marleen Kok
Summary: A significant proportion of early-stage triple-negative breast cancer patients have high levels of tumor-infiltrating lymphocytes, indicating a strong endogenous immune response against cancer. Immune-checkpoint inhibition combined with chemotherapy has become the standard of care for these patients. Future challenges include identifying which patients can be treated with immune-checkpoint inhibition alone or with reduced chemotherapy, determining the optimal duration of treatment, and finding biomarkers for treatment response prediction. For patients who do not respond effectively to current treatment, developing new immunomodulatory therapies and response-guided neoadjuvant approaches are needed.
CLINICAL CANCER RESEARCH
(2023)
Article
Cell Biology
Baochun Zhang, Dinis Pedro Calado, Zhe Wang, Sebastian Froehler, Karl Koechert, Yu Qian, Sergei B. Koralov, Marc Schmidt-Supprian, Yoshiteru Sasaki, Christine Unitt, Scott Rodig, Wei Chen, Riccardo Dalla-Favera, Frederick W. Alt, Laura Pasqualucci, Klaus Rajewsky
Article
Oncology
Zhaoqing Ba, Fei-Long Meng, Monica Gostissa, Pei-Yi Huang, Qiang Ke, Zhe Wang, Mai N. Dao, Yuko Fujiwara, Klaus Rajewsky, Baochun Zhang, Frederick W. Alt
CANCER IMMUNOLOGY RESEARCH
(2015)
Review
Oncology
Laura Pasqualucci, Baochun Zhang
SEMINARS IN CANCER BIOLOGY
(2016)
Article
Multidisciplinary Sciences
Il-Kyu Choi, Zhe Wang, Qiang Ke, Min Hong, Yu Qian, Xiujuan Zhao, Yuting Liu, Hye-Jung Kim, Jerome Ritz, Harvey Cantor, Klaus Rajewsky, Kai W. Wucherpfennig, Baochun Zhang
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2018)
Article
Pathology
Liqun Yang, Hongjuan Cui, Zhe Wang, Baochun Zhang, Jane Ding, Lin Liu, Han-Fei Ding
AMERICAN JOURNAL OF PATHOLOGY
(2010)
Article
Oncology
Dinis Pedro Calado, Baochun Zhang, Lakshmi Srinivasan, Yoshiteru Sasaki, Jane Seagal, Christine Unitt, Scott Rodig, Jeffery Kutok, Alexander Tarakhovsky, Marc Schmidt-Supprian, Klaus Rajewsky
Article
Oncology
Sandrine Sander, Dinis P. Calado, Lakshmi Srinivasan, Karl Koechert, Baochun Zhang, Maciej Rosolowski, Scott J. Rodig, Karlheinz Holzmann, Stephan Stilgenbauer, Reiner Siebert, Lars Bullinger, Klaus Rajewsky
Article
Biochemistry & Molecular Biology
Lakshmi Srinivasan, Yoshiteru Sasaki, Dinis Pedro Calado, Baochun Zhang, Ji Hye Paik, Ronald A. DePinho, Jeffrey L. Kutok, John F. Kearney, Kevin L. Otipoby, Klaus Rajewsky
Article
Biochemistry & Molecular Biology
Baochun Zhang, Sven Kracker, Tomoharu Yasuda, Stefano Casola, Matthew Vanneman, Cornelia Homig-Holzel, Zhe Wang, Emmanuel Derudder, Shuang Li, Tirtha Chakraborty, Shane E. Cotter, Shohei Koyama, Treeve Currie, Gordon J. Freeman, Jeffery L. Kutok, Scott J. Rodig, Glenn Dranoff, Klaus Rajewsky
Article
Multidisciplinary Sciences
Robin Graf, Jane Seagal, Kevin L. Otipoby Section, Kong-Peng Lam, Salah Ayoub, Baochun Zhang, Sandrine Sander, Van Trung Chu, Klaus Rajewsky
Article
Multidisciplinary Sciences
Il-Kyu Choi, Zhe Wang, Qiang Ke, Min Hong, Dereck W. Paul, Stacey M. Fernandes, Zhuting Hu, Jonathan Stevens, Indira Guleria, Hye-Jung Kim, Harvey Cantor, Kai W. Wucherpfennig, Jennifer R. Brown, Jerome Ritz, Baochun Zhang
Editorial Material
Immunology
Baochun Zhang, Il-Kyu Choi, Jutatip Panaampon, Zhe Wang
Summary: Childhood cancer is increasing in high-income countries, possibly due to reduced exposure to common infections in early life. The specific infection responsible for cancer protection has not been identified, but recent findings suggest that delayed Epstein-Barr virus (EBV) infection might contribute to the rise in childhood cancers.
TRENDS IN IMMUNOLOGY
(2022)
